Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE Phase 3 OV101 in pediatric Angelman syndrome
NL-OMON49584Phase 3Active, not recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Angelman syndrome (AS) comparing OV101 with Placebo (2 arms). Primary endpoint: Clinical Global Impressions-Improvement-Angelman syndrome score. Started Jul 2020; status: active, not recruiting.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NL-OMON49584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49584.